Answers are grounded in this paper and cite their sources.
BACKGROUND: Guselkumab, a selective interleukin (IL)-23 inhibitor, is approved for the treatment of moderate-to-severe plaque psoriasis. While randomized clinical trials have introduced the concept of "super-responders" (SRe)-patients achieving complete skin clearance (Psoriasis Area and Severity Index [PASI] 100) at defined early timepoints-real-world evidence on their characteristics and long-term outcomes remains limited. This study aimed to identify baseline predictors of super-response (PASI 100 at Weeks 16 and 24) and to evaluate long-term effectiveness, safety, and drug survival over a 5-year period in a routine clinical setting. METHODS: This retrospective multicenter study analyzed 435 patients from the Czech BIOREP registry treated with guselkumab. Predictors of super-response were identified using multivariable logistic regression. PASI outcomes and drug survival were assessed with descriptive statistics and Kaplan-Meier analysis. RESULTS: Among the cohort, 130 patients (29.9%) were classified as super-responders. Lower body mass index (BMI) and absence of prior biologic therapy were independent predictors of SRe status (odds ratio [OR] = 0.94 and 0.73, respectively). While PASI 75/90/100 rates were significantly higher in SRe throughout follow-up, drug survival was comparable between SRe and non-SRe. At 60 months, PASI 100 was maintained in 79.2% of SRe versus 35.4% of non-SRe. Obesity and female sex were associated with lower long-term treatment persistence. CONCLUSIONS: Super-response to guselkumab is linked to distinct baseline features. Despite differences in PASI outcomes, treatment persistence was similar across groups. These findings underscore the value of early identification of super-responders and support personalized treatment strategies in clinical practice.
No takes yet. Share an insight, caveat, or question.
Kojanová et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: